ShengFengCaiMDPhD

PubMed

• 2 citations
  A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
  Cai, S., Huang, Y., Lance, J., Mao, H., Dunbar, A., McNulty, S., Druley, T., Li, Y., Baer, M., Stock, W., Kovacsovics, T., Blum, W., Schiller, G., Olin, R., Foran, J.,...> ;Blood Advances. 2024 Jan 23
• 2 citations
  Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms.
  Andrew J Dunbar, Robert L Bowman, Young C Park, Kavi O'Connor, Franco Izzo, Robert M Myers, Abdul Karzai, Zach Zaroogian, Won Jun Kim, Ines Fernandez-Maestre, Michael ...> ;Cancer Discovery. 2024 Jan 12
• 6 citations
  Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia.
  Troy M Robinson, Robert L Bowman, Sonali Persaud, Ying Liu, Rosemary Neigenfind, Qi Gao, Jingping Zhang, Xiaotian Sun, Linde A Miles, Sheng F Cai, Adam Sciambi, Aaron ...> ;Science Advances. 2023 Sep 22
• 5 citations
  Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.
  Joseph G W McCarter, David Nemirovsky, Christopher A Famulare, Noushin Farnoud, Abhinita S Mohanty, Zoe S Stone-Molloy, Jordan Chervin, Brian J Ball, Zachary D Epstein...> ;Blood Advances. 2023 Sep 12
• 2 citations
  Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
  Maximilian Stahl, Andriy Derkach, Noushin Farnoud, Jan Philipp Bewersdorf, Troy Robinson, Christopher Famulare, Christina Cho, Sean Devlin, Kamal Menghrajani, Minal A ...> ;American Journal of Hematology. 2023 Jan 1
• 4 citations
  Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance.
  Junhua Lyu, Yuxuan Liu, Lihu Gong, Mingyi Chen, Yazan F Madanat, Yuannyu Zhang, Feng Cai, Zhimin Gu, Hui Cao, Pranita Kaphle, Yoon Jung Kim, Fatma N Kalkan, Helen Step...> ;Cancer Discovery. 2023 Jan 9
• 6 citations
  BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation.
  Bing Li, Wenbin An, Hua Wang, Timour Baslan, Shoron Mowla, Aishwarya Krishnan, Wenbin Xiao, Richard P Koche, Ying Liu, Sheng F Cai, Zhijian Xiao, Andriy Derkach, Ilari...> ;Blood. 2022 Jun 23
• 23 citations
  Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistan...
  Evelyn M Nguyen, Hirokazu Taniguchi, Joseph M Chan, Yingqian A Zhan, Xiaoping Chen, Juan Qiu, Elisa de Stanchina, Viola Allaj, Nisargbhai S Shah, Fathema Uddin, Parvat...> ;Journal of Thoracic Oncology. 2022 Aug 1
• 16 citations
  Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.
  Jan Philipp Bewersdorf, Andriy Derkach, Lohith Gowda, Kamal Menghrajani, Susan DeWolf, Josel D. Ruiz, Doris M. Ponce, Brian C. Shaffer, Roni Tamari, James W. Young, An...> ;Leukemia & Lymphoma. 2021 Sep 3
• 89 citations
  Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
  Maximilian Stahl, Kamal Menghrajani, Andriy Derkach, Alexander Chan, Wenbin Xiao, Jacob L. Glass, Amber C. King, Anthony F. Daniyan, Christopher Famulare, Bernadette M...> ;Blood Advances. 2021 Mar 9
• 6 citations
  The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy.
  Brian Ball, Meier Hsu, Sean M. Devlin, Maria E. Arcila, Mikhail Roshal, Yanming Zhang, Chris A Famulare, Aaron D Goldberg, Sheng F. Cai, Andrew Dunbar, Zachary D. Epst...> ;American Journal of Hematology. 2021 Mar 1
• 3 citations
  A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN.
  Wenbin Xiao, Linde A. Miles, Robert L. Bowman, Vidushi Durani, Helen S. Tian, Nicole L. DelGaudio, Tanmay Mishra, Menglei Zhu, Yanming Zhang, Sarah E. Stump, Martin S....> ;Blood Advances. 2020 Dec 8
• 38 citations
  Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia.
  Wenbin Xiao, Alexander Chan, Michael R. Waarts, Tanmay Mishra, Ying Liu, Sheng F. Cai, Jinjuan Yao, Qi Gao, Robert L. Bowman, Richard Koche, Isabelle S. Csete, Nicole ...> ;Blood. 2021 Mar 11
• 5 citations
  BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon.
  Michele Stanchina, Jae H. Park, Eytan M. Stein, Sheng F. Cai, Justin Taylor> ;Leukemia Research Reports. 2020 Jun 8
• 19 citations
  Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition
  Sheng F. Cai, S. Haihua Chu, Aaron D Goldberg, Salma Parvin, Richard Koche, Jacob L. Glass, Eytan M. Stein, Martin S. Tallman, Filiz Sen, Christopher Famulare, Monica ...> ;Cancer Discovery. 2020 Oct 1
• 6 citations
  RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy
  Brian Ball, Meier Hsu, Sean M. Devlin, Christopher Famulare, Sheng F. Cai, Andrew Dunbar, Zachary D. Epstein-Peterson, Kamal Menghrajani, Jacob L. Glass, Justin Taylor...> ;Blood. 2019 Nov 13
• 12 citations
  Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia.
  Wenbin Xiao, Aaron D Goldberg, Christopher Famulare, Sean M. Devlin, Nghia T. Nguyen, Sinnifer Sim, Charlene C. Kabel, Minal Patel, Erin McGovern, Akshar Patel, Jessic...> ;Haematologica. 2019 Jul 1
• 60 citations
  Genetic and epigenetic determinants of AML pathogenesis
  Sheng F. Cai, Ross L. Levine> ;Seminars in Hematology. 2019 Apr 1
• 81 citations
  HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis
  Yuqing Sun, Bo Zhou, Fengbiao Mao, Jing Xu, Hongzhi Miao, Zhenhua Zou, Le Tran Phuc Khoa, Younghoon Jang, Sheng Cai, Matthew Witkin, Richard Koche, Kai Ge, Gregory R. ...> ;Cancer Cell. 2018 Oct 8
• 2 citations
  Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation.
  Wenbin Xiao, Mariko Yabe, Michael Offin, Pallavi Khattar, Jeeyeon Baik, Ryan J. Daley, Jeremy J. Pappacena, Mikhail Roshal, Yanming Zhang, Martin S. Tallman, Sheng F. Cai> ;Blood Advances. 2018 Jul 10
• 73 citations
  LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.
  Monica Cusan, Sheng F. Cai, Helai P. Mohammad, Andrei V. Krivtsov, Alan Chramiec, Evangelia Loizou, Matthew Witkin, Kimberly N. Smitheman, Daniel G. Tenen, Min Ye, Bri...> ;Blood. 2018 Apr 12
• 39 citations
  Drugging Chromatin in Cancer: Recent Advances and Novel Approaches
  Sheng F. Cai, Chun-Wei Chen, Scott A. Armstrong> ;Molecular Cell. 2015 Nov 19
• 14 citations
  Mechanism of E1-E2 Interaction for the Inhibition of Ubl Adenylation
  Jianghai Wang, Sheng Cai, Yuan Chen> ;The Journal of Biological Chemistry. 2010 Oct 22
• 25 citations
  Granzyme B is not required for regulatory T cell–mediated suppression of graft-versus-host disease
  Sheng F. Cai, Xuefang Cao, Anjum Hassan, Todd A. Fehniger, Timothy J. Ley> ;Blood. 2010 Mar 4
• 60 citations
  Interleukin 12 Stimulates IFN-γ–Mediated Inhibition of Tumor-Induced Regulatory T-Cell Proliferation and Enhances Tumor Clearance
  Xuefang Cao, Karen Leonard, Lynne Collins, Sheng F. Cai, Joshua C. Mayer, Jacqueline E. Payton, Michael J. Walter, David Piwnica-Worms, Robert D. Schreiber, Timothy J....> ;Cancer Research. 2009 Nov 15
• Join now to see all

Journal Articles

• Article HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis  
  Ross L Levine, Jay L Hess, Sheng Cai, Scott A Armstrong, ScienceDirect

Abstracts/Posters

• Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism
  Sheng F. Cai, MD, PhD, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia
  Sheng F Cai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018